Organization
Valencia, Spain
5 abstracts
Abstract
Comparing 18F-FDG positron emission tomography (PET) and breast magnetic resonance imaging (MRI) to predict pathological complete response (pCR) and 3-year invasive disease-free survival (3-y iDFS) in patients (pts) with HER2+ early breast cancer (EBC): An unplanned exploratory analysis of PHERGain trial.Org: International Breast Cancer Center (IBCC), Pangaea Oncology, Quiron Group, Medica Scientia Innovation Research (MEDSIR) - Oncoclínicas&Co, Jersey City (New Jersey, USA),
Abstract
Atezolizumab versus placebo in combination with bevacizumab and non-platinum-based chemotherapy in recurrent ovarian cancer: Final overall and progression-free survival results from the AGO-OVAR 2.29/ENGOT-ov34 study.Org: GEICO, Arcagy-Gineco, NSGO-CTU, SAKK, BGOG,
Abstract
Use of liquid biomarker thymidine kinase activity (TKa) to predict outcome and progression in patients with metastatic breast cancer (MBC) in the GEICAM/2014-12 FLIPPER trial.Org: Hospital del Mar, Barcelona, Spain, CIBERONC-ISCIII, Biovica International AB, Hospital Clínico Universitario de Valencia, INCLIVA-Biomedical Research Institute,
Abstract
Phase 2 study of elraglusib (9-ING-41), a glycogen synthase kinase-3b inhibitor, in combination with gemcitabine plus nab-paclitaxel (GnP) in patients with previously untreated advanced pancreatic ductal adenocarcinoma (PDAC).Org: Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Robert H Lurie Comprehensive Cancer Center, Chicago, IL, University of Pittsburgh Medical Center (UPMC), Department of Medicine, Icahn School of Medicine at Mount Sinai,
Abstract
18 fdg pet/ct predicts decline in functional respiratory tests in systemic sclerosis patients but not in rheumatoid arthritis patientsOrg: Rheumatology Department, Pneumology Department, Centre Hospitalier Toulon Sainte-Musse, Nuclear Medicine Department, HUP La Fe, Valencia, Spain,